Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,664.12๏ฟฅ. Average daily volumn in 3 months 2.46M. Market cap 5.96T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,626.00๏ฟฅ. Total volume : 4.24M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
3,626.00๏ฟฅ
Change
-4.00
Volume
4.24M

Previous Close3,630.00
Open3,637.00
Day Range3,608.00-3,679.00
Bid3,612.00 x N/A
Ask3,628.00 x N/A
Volume4.24M
Average Volume2.46M
Market Cap5.96T
BetaN/A
52 Week Range3,258.00-4,399.00
Trailing P/E15.34
Foward P/E18.55
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2021 were 999.76B an increase( +27.1%) over the years 2020 revenue that were of 786.95B. In 2021 the company's total earnings were 303B while total earnings in 2020 were 214.73B( +41.59%).


Loading ...



Organization

Market Cap:
5.96T
Revenue:
999.76B
Total Assets:
1.54T
Total Cash:
267.75B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Source from : Nikkei Asia - 9 days ago

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...See details»


Chugai Pharmaceutical

Source from : Forbes - 18 days ago

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals products. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems.See details»


Chugai Pharmaceutical Co., Ltd. Forecasted to Earn Q3 2022 Earnings of $0.17 Per Share (OTCMKTS:CHGCY)

Source from : Defense World - 7 days ago

Analysts at Jefferies Financial Group issued their Q3 2022 earnings estimates for shares of Chugai Pharmaceutical in a research note issued to investors on Tuesday, September 20th. Jefferies Financial ...See details»


Chugai files NDA in Japan for fixed-dose subcutaneous combination of pertuzumab & trastuzumab for HER2-positive breast and colorectal cancer

Source from : Pharmabiz - 1 days ago

Chugai files NDA in Japan for fixed-dose subcutaneous combination of pertuzumab & trastuzumab for HER2-positive breast and colorectal cancer: Tokyo Friday, September 30, 2022, 12: ...See details»


Chinaโ€™s Supreme Peopleโ€™s Court upholds first patent linkage ruling decision on Chugai-Haihe dispute

Source from : BioWorld - 24 days ago

China has upheld a recent ruling on a dispute between Chugai Pharmaceutical Co. Ltd. and Wenzhou Haihe Pharmaceutical Co. Ltd. over a generic form of an osteoporosis treatment. The move is seen as an ...See details»


Japan Pharmaceutical Market Size Is Likely to Experience a Tremendous Growth by 2031 Covid-19 Analysis

Source from : MarketWatch - 10 days ago

The Japan Pharmaceutical market studied was anticipated to show a slow growth with a CAGR of 1.06%. In Japan, the pharmaceutical industry has experienced modest growth patterns in recent years. Strong ...See details»


chugai-pharma-taiwan-awarded-at-the-asia-responsible-enterprise-awards-2022-for-cycling-for-charity-under-social-empowerment-category-image

Chugai Pharma Taiwan Awarded at the Asia Responsible Enterprise Awards 2022 for 'Cycling for Charity' under Social Empowerment Category

Source from : vietreader.com - 3 days ago

The Asia Responsible Enterprise Awards (AREA) 2022 is pleased to honor 72 exemplary award recipients for championing ESG to build a resilient world and a sustainable future for all. The AREA is the mo ...See details»


Joint Pain Injections Global Market Report 2022

Source from : Benzinga.com - 4 days ago

The "Joint Pain Injections Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior ...See details»


Unresectable Hepatocellular Carcinoma Treatment Market Key Player, Competition Weakness and Strengths from 2022 to 2028

Source from : MarketWatch - 11 days ago

This " Unresectable Hepatocellular Carcinoma Treatment Market " includes premium insights into different segments in terms of overall growth, development, opportunity, and business strategies, for the ...See details»


$4.6 Billion Worldwide Joint Pain Injections Industry to 2031 - North America was the Largest Market in 2031

Source from : Benzinga.com - 12 days ago

The "Joint Pain Injections Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers ...See details»


glycomic-therapeutics-market-forecast-to-2028-covid-19-impact-and-global-analysis-by-class-structure-indications-and-mode-of-action-image

Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structure, Indications, and Mode of Action

Source from : Yahoo Finance - 4 days ago

The global glycomic therapeutics market is expected to grow from US$ 99,021. 46 million in 2021 to US$ 257,578. 79 million in 2028; it is estimated to grow with a CAGR of 15. 8% from 2022 to 2028.New ...See details»


Chugai Pharmaceutical Co Ltd

Source from : Reuters - 11 days ago

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products ...See details»


Chugai Pharmaceutical Co. Ltd. ADR

Source from : Wall Street Journal - 10 days ago

1 Day CHGCY -3.07% DJIA -1.01% S&P 500 -1.13% Health Care/Life Sciences 0.31% Tatsuro Kosaka Chairman & Chief Executive Officer Mitsubishi Electric Corp., Chugai Pharmaceutical Co., Ltd. Osamu ...See details»


Chugai Pharmaceutical Co., Ltd. (4519.T)

Source from : Yahoo Finance - 4 days ago

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...See details»